Drugs / Vixotrigine
Vixotrigine
also known as
BIIB074 · CNV1014802 · GSK1014802 · BIIB-074 HYDROCHLORIDE · CNV-1014802 HYDROCHLORIDE · CNV-1014802A · GSK-1014802 HYDROCHLORIDE · GSK-1014802A · +4 more
Small molecule targets SCN9A via inhibition
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT04106050 | Sep 2020 → Jan 2022 | diabetic polyneuropathy | Biogen | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03324685 | Nov 2017 → Mar 2018 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT03385525 | Sep → Oct 2017 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02831517 | Aug 2016 → Feb 2017 | trigeminal neuralgia | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02751905 | Apr → May 2016 | neuropathy, painful | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02698267 | Feb → Apr 2016 | neuropathy, painful | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02551497 | Apr 2015 → Aug 2016 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02359344 | Feb → Apr 2015 | trigeminal neuralgia | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00955396 | Jul → Dec 2009 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00964288 | Jul → Nov 2009 | neuropathy, painful | Biogen | Terminated | No outcome recorded |
| Phase 1 | NCT00908154 | May → Dec 2008 | bipolar depression | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00488566 | May 2007 → May 2008 | bipolar disorder | Biogen | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT03339336 | May 2018 → Apr 2021 | diabetes mellitus, neuropathy, small fiber | Biogen | Terminated | Mixed Stop: Business |
| Phase 2 | NCT02957617 | Feb 2017 → Feb 2019 | radiculopathy | Biogen | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02935608 | Oct 2016 → Aug 2018 | radiculopathy | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT02917187 | Sep → Dec 2016 | primary erythermalgia | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT01540630 | Mar 2012 → Mar 2014 | trigeminal neuralgia | Biogen | Completed | Missed primary |
| Phase 2 | NCT01561027 | Apr 2011 → Jun 2012 | radiculopathy | Biogen | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03070132 | Apr 2023 → Oct 2025 | trigeminal neuralgia | Biogen | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03637387 | Mar 2023 → Aug 2025 | trigeminal neuralgia | Biogen | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-16 | Biogen | Results Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy biogen.com ↗
The CONVEY study 200 mg twice daily arm met its primary endpoint of change from baseline to week 12 of the double-blind period in mean average daily pain (ADP) score. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-16 | Biogen | Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy biogen.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vixotrigine | “Vixotrigine is a voltage- and use-dependent sodium channel blocker in development for neuropathic pain management.” PMID 32564301 ↗ Aug 20201“BIIB074 (Vixotrigine)” NCT02957617 ↗ |
| Known as | BIIB-074 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | BIIB074 | “BIIB074, a Nav1.7-selective, state-dependent sodium-channel blocker, can be administered at therapeutic doses without titration, and has shown good tolerability in healthy...” PMID 28216232 ↗ Feb 2017 |
| Known as | CNV-1014802 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | CNV-1014802A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | CNV1014802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01540630 ↗ |
| Known as | GSK-1014802 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | GSK-1014802A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | GSK1014802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00908154 ↗ |
| Known as | Raxatrigine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | RAXATRIGINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | Vixotrigina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Known as | Vixotrigine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544913 ↗ |
| Action | Inhibit | “BIIB074, a Nav1.7-selective, state-dependent sodium-channel blocker” PMID 28216232 ↗ Feb 20171“Sodium channel protein type IX alpha subunit blocker” CHEMBL3544913 ↗ |
| Modality | Small molecule | — CHEMBL3544913 ↗ |
| Route | Oral | “single oral dose” NCT00488566 ↗ |
| Target | SCN9A | “Sodium channel protein type IX alpha subunit blocker” CHEMBL3544913 ↗ |